Halobetasol 0.01%/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy

Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safety remains a concern, limiting use, and posttreatment flare common. Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment. Fixed combination therapy with TCS may improve psoriasis signs and may maintain a therapeutic effect while minimizing posttreatment flare or rebound
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research